Akums Drugs Subsidiary Faces Rs 52.75 Crore NPPA Demand

Total demand includes Rs 18.95 crore overcharging amount plus equal penalty and interest. The notice involves the 'Lanol 1000 mg injection' 100ml formulation manufactured by Pure and Cure Healthcare.

Reader Takeaway: Subsidiary faces significant regulatory demand while the parent company points to contractual indemnity from the marketer.

What just happened

The National Pharmaceutical Pricing Authority (NPPA) has issued a demand notice of Rs 52.75 crore to Pure and Cure Healthcare, a wholly-owned subsidiary of Akums Drugs and Pharmaceuticals. The notice, dated October 13, 2026, alleges that the 'Lanol 1000 mg injection' was marketed without obtaining mandatory prior price approval as required under Section 15 of The Drugs (Prices Control) Order, 2013.

Why this matters

The notice highlights potential regulatory risks in the pharmaceutical manufacturing sector, specifically concerning price compliance. The total demand includes Rs 18.95 crore in alleged overcharging, an equal amount in penalties, and Rs 14.85 crore in interest, creating a financial visibility concern for the subsidiary's operations.

Company Position and Indemnity

Akums Drugs has clarified that the marketer, Hetero Healthcare Limited, holds primary responsibility for this notice. The company maintains that its supply agreements include indemnity clauses, which make the marketing entity solely liable for any fines, penalties, or interest related to discrepancies in the maximum retail price of the supplied products.

Risks to watch

Investors should monitor whether the indemnity clauses are legally upheld during the NPPA proceedings. Any failure to enforce these agreements could force the subsidiary to settle the demand, directly impacting its financial health. The regulatory scrutiny on the manufacturing subsidiary remains a key variable for investors to track as the legal process unfolds.